Exelixis ((EXEL)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Exelixis is currently conducting a clinical study titled ‘A Dose Escalation and Expansion Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors.’ The study aims to evaluate the safety and tolerability of the drug XB371 in patients with advanced solid tumors, which is crucial for determining its potential as a treatment option.
The intervention being tested is XB371, administered as an intravenous infusion. This drug is designed to treat locally advanced or metastatic solid tumors, with the goal of establishing a safe dosage and understanding its effects on patients.
The study follows an interventional design with a sequential intervention model. It is primarily focused on treatment, with no masking involved, meaning all participants and researchers know the treatment being administered. The study includes both non-randomized dose-escalation cohorts and randomized dose-expansion cohorts.
The study began on August 8, 2025, and the latest update was submitted on August 27, 2025. These dates mark the study’s initiation and the most recent information available, indicating ongoing progress in the trial.
This study update could influence Exelixis’s stock performance and investor sentiment, as successful results may enhance the company’s portfolio in the oncology sector. Investors should watch for further developments, especially in comparison to competitors in the cancer treatment market.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.